Skip to main content
SpringerLink
Log in
Book cover

Arzneiverordnungs-Report 2007 pp 845–867Cite as

Sexualhormone

  • Chapter

  • 554 Accesses

Auszug

Die wichtigsten Gruppen der Sexualhormone sind Östrogenpräparate und Kontrazeptiva. Danach folgen mit weitem Abstand Gestagene, Antiöstrogene und Androgene.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Archer DF (2007): Drospirenone, a progestin with added value for hypertensive postmenopausal women. Menopause 14: 352–354.

    Article  PubMed  Google Scholar 

  • Arzneimittelkommission der Deutschen Ärzteschaft (2003): Rote Hand Brief zur Hormontherapie im Klimakterium vom 09.12.2003. Im Internet: www.akdae. de/20/40/index.html.

    Google Scholar 

  • Castelo-Branco C, Vicente JJ, Figueras F, Sanjuan A, Martinez de Osaba MJ, Casals E et al (2000): Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 34: 161–168.

    Article  PubMed  CAS  Google Scholar 

  • Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR (1995): Estrogen replacement therapy and fractures in older women. Ann Intern Med 122: 9–16.

    PubMed  CAS  Google Scholar 

  • Cheng L, Gulmezoglu AM, Oel CJ, Piaggio G, Ezcurra E, Look PF (2004): Interventions for emergency contraception. Cochrane Database Syst Rev. 2004; (3): CD001324.

    Google Scholar 

  • Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F; WHO International Agency for Research on Cancer (2005): Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 6: 552–553.

    Article  PubMed  Google Scholar 

  • Collaborative Study Group on the Desogestrel-containing Progesteron-only Pill (1998): A double blind study comparing the contraceptive efficacy, acceptability and safety of two progesteron-only pills containing desogestrel 75 micrograms/ day or levonorgestrel 30 micrograms/day. Eur J Contracept Reprod Health Care 3: 169–178.

    Article  Google Scholar 

  • Dinger JC, Heinemann LA, Kuhl-Habich D (2007): The safety of a drospirenonecontaining oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 75: 344–354.

    Article  PubMed  CAS  Google Scholar 

  • Fisher B, Constantino JP, Wickerham LD, Redmond CK et al (1998): Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer I 90: 1371–1388.

    Article  CAS  Google Scholar 

  • Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ (2000): A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 133: 933–1001.

    PubMed  CAS  Google Scholar 

  • Howell A, Robertson JFR, Quaresma Albano J, Aschermannova A, Mauriac L et al. (2002): Fulvestrant (ICI 182,780) is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing progressing after prior endocrine treatment. J Clin Oncol 20: 3396–3403.

    Article  PubMed  CAS  Google Scholar 

  • Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R et al. (2004): Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22: 1605–1613.

    Article  PubMed  CAS  Google Scholar 

  • Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, Eaton CB, Kostis JB, Caralis P, Prentice R; Women’s Health Initiative Investigators (2006): Conjugated equine estrogens and coronary heart disease: the Women’s Health Initiative. Arch Intern Med 166: 357–365.

    Article  PubMed  CAS  Google Scholar 

  • Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E (1998): Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280: 605–613.

    Article  PubMed  CAS  Google Scholar 

  • Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C (1995): Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346: 1589–1593.

    Article  PubMed  CAS  Google Scholar 

  • Kemmeren JM, Algra A, Grobbee DE (2001): Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Brit Med J 323: 1–9.

    Article  Google Scholar 

  • König HJ (1991): Hirnkreislaufstörungen unter Einnahme gestodenhaltiger hormonaler oraler Kontrazeptiva — Kausalität oder Koinzidenz? Dtsch Ärztebl 91: C–1745–1748.

    Google Scholar 

  • Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M; Women’s Health Initiative Investigators (2003): Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349: 523–534.

    Article  PubMed  CAS  Google Scholar 

  • Million Women Study Collaborators (2003): Breast cancer and hormone-replacement in the Million Women Study. Lancet 362: 419–427.

    Article  CAS  Google Scholar 

  • Million Women Study Collaborators (2005): Endometrial cancer and hormonereplacement therapy in the Million Women Study. Lancet 365: 1543–1551.

    Article  CAS  Google Scholar 

  • Million Women Study Collaborators (2007): Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369: 1703–1710.

    Article  CAS  Google Scholar 

  • Modelska K, Cummings S (2002): Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab. 87:16–23.

    Article  PubMed  CAS  Google Scholar 

  • NAMS Advisory Panel (2003): Amended report from the NAMS Advisory Panel on postmenopausal hormone therapy. Menopause 10: 6–12.

    Google Scholar 

  • Nelson HD (2004): Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 291: 1610–1620.

    Article  PubMed  CAS  Google Scholar 

  • Oddsson K, Leifels-Fischer B, de Melo NR, Wiel-Masson D, Benedetto C, Verhoeven CH, Dieben TO (2005): Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 71: 176–182.

    Article  PubMed  CAS  Google Scholar 

  • Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R (1995): Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the rennin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 80: 1816–1821.

    Article  PubMed  CAS  Google Scholar 

  • Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M et al. (2002): A double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant with anastrozole in post-menopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 20: 3386–3395.

    Article  PubMed  CAS  Google Scholar 

  • Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML (2007): Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297: 1465–1477.

    Article  PubMed  CAS  Google Scholar 

  • Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA (2007): The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356: 1670–1674.

    Article  PubMed  CAS  Google Scholar 

  • Royal College of General Practitioners Oral Contraception Study (1981): Further analysis of mortality in oral contraceptive users. Lancet I: 541–546.

    Google Scholar 

  • Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F (2004): Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 89: 5429–5434.

    Article  PubMed  CAS  Google Scholar 

  • Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD (1996): Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Brit Med J 312: 83–88.

    PubMed  CAS  Google Scholar 

  • Tang M-X, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H (1996): Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet 348: 429–432.

    Article  PubMed  CAS  Google Scholar 

  • Van Grootheest K, Vrieling T (2003): Thromboembolism associated with the new contraceptive Yasmin. BMJ 326: 257.

    Article  PubMed  Google Scholar 

  • World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1995): Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346: 1582–1588.

    Article  Google Scholar 

  • Womens Health Initiative Steering Committee (2004): Effect of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative randomized controlled trial. JAMA 291: 1701–1712.

    Article  Google Scholar 

  • Writing Group for the Women’s Health Initiative (2002): Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288: 321–333.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Prof. Dr. med. Ulrich Schwabe

Authors
  1. Prof. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK Schleswig-Holstein Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Schwabe, U. (2008). Sexualhormone. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2007. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72548-0_45

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-72548-0_45

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-72547-3

  • Online ISBN: 978-3-540-72548-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation